Lite Strategy, Inc. Deferred Revenue, Revenue Recognized
Lite Strategy, Inc. (LITS) reported Deferred Revenue, Revenue Recognized of $64.90 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-26.
Discontinued › Income Statement › Other Income
us-gaap:DeferredRevenueRevenueRecognized1 · last filed 2023-09-26
- Lite Strategy, Inc. deferred revenue, revenue recognized for the quarter ending 2022-09-30 was $94.50M, a 5.12% decline year-over-year.
- Lite Strategy, Inc. deferred revenue, revenue recognized for the quarter ending 2021-09-30 was $99.60M.
- Lite Strategy, Inc. deferred revenue, revenue recognized for fiscal 2023 was $64.90M, a 31.97% decline from fiscal 2022.
- Lite Strategy, Inc. deferred revenue, revenue recognized for fiscal 2022 was $95.40M, a 20.45% increase from fiscal 2021.
- Lite Strategy, Inc. deferred revenue, revenue recognized for fiscal 2021 was $79.20M.
| Period end | Deferred Revenue, Revenue Recognized 3 month | Deferred Revenue, Revenue Recognized 3 month as first filed | Deferred Revenue, Revenue Recognized 6 month | Deferred Revenue, Revenue Recognized 6 month as first filed | Deferred Revenue, Revenue Recognized 9 month | Deferred Revenue, Revenue Recognized 12 month | Deferred Revenue, Revenue Recognized 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | $64.90M 10-K · filed 2023-09-26 | ||||||
| 2023-03-31 | $66.10M 10-Q · filed 2023-05-11 | ||||||
| 2022-12-31 | $67.40M 10-Q · filed 2023-02-09 | ||||||
| 2022-09-30 | $94.50M 10-Q · filed 2022-11-14 | ||||||
| 2022-06-30 | $95.40M 10-K · filed 2023-09-26 | ||||||
| 2022-03-31 | $96.70M 10-Q · filed 2022-05-23 | ||||||
| 2021-12-31 | $98.00M 10-Q/A · filed 2022-05-23 | $94.00M 10-Q · filed 2022-02-10 | |||||
| 2021-09-30 | $99.60M 10-Q/A · filed 2022-05-23 | $102.10M 10-Q · filed 2021-11-10 | |||||
| 2021-06-30 | $79.20M 10-K · filed 2022-09-08 | $87.30M 10-K · filed 2021-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |